Applied DNA Sciences and IHBT present cost-effective CAR T-cell therapy production research using Linea DNA at the European Hematology Association Congress.
Applied DNA Sciences & the Institute of Hematology & Blood Transfusion are presenting research on a non-viral, enzymatic method for cost-effective CAR T-cell therapy production at the European Hematology Association Congress. Utilizing Linea DNA, they aim to address high costs of viral vector-based therapies, potentially reducing production time and offering a solution for refractory acute myeloid leukemia.
May 13, 2024
3 Articles